{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:21Z","timestamp":1753891761714,"version":"3.41.2"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00939","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T13:14:13Z","timestamp":1591967653000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Editorial: Emerging Therapies for Malignant Mesothelioma"],"prefix":"10.3389","volume":"10","author":[{"given":"Nico","family":"van Zandwijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/1097-01421991041567:82033::aid-cncr28206708043.0.co;2-8","article-title":"Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma","volume":"67","author":"Boutin","year":"1991","journal-title":"Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3892\/ijo.6.2.431","article-title":"Natural-killer cell-mediated cytotoxicity of blood-lymphocytes from patients with malignant mesothelioma treated by intrapleural interleukin-2","volume":"6","author":"Astoul","year":"1995","journal-title":"Int J Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1002\/1097-01421994110174:92460::aid-cncr28207409123.0.co;2-n","article-title":"Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma","volume":"74","author":"Boutin","year":"1994","journal-title":"Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/(sici)1097-01421998111583:102099::aid-cncr83.0.co;2-3","article-title":"Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"83","author":"Astoul","year":"1998","journal-title":"Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","article-title":"National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study","volume":"105","author":"Saddoughi","year":"2018","journal-title":"Ann Thorac Surg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-20451170149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S1470-20451170307-2","article-title":"The MARS feasibility trial: conclusions not supported by data","volume":"12","author":"Weder","year":"2011","journal-title":"Lancet Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/annonc\/mdy195","article-title":"Pleural mesothelioma: is the surgeon still there?","volume":"29","author":"Opitz","year":"2018","journal-title":"Ann Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-67361501238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S1470-20451830100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-20451730621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T13:14:15Z","timestamp":1591967655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":14,"alternative-id":["10.3389\/fonc.2020.00939"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00939","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"article-number":"939"}}